Hormone Therapy With Arzoxifene Hydrochloride in Treating Women With Metastatic Refractory Ovarian Cancer or Primary Peritoneal Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Andrzej P. Kudelka, MD
M.D. Anderson Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ellis Fischel Cancer Center - Columbia
Columbia, Missouri, United States
- Lineberger Comprehensive Cancer Center, Unc
Chapel Hill, North Carolina, United States
- Abington Memorial Hospital
Abington, Pennsylvania, United States
- University of Texas - Md Anderson Cancer Center
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 1998
- Primary completion
- —
- Completion
- 31 Jan 2001
- Last update posted
- 7 Jun 2012
- Registered enrollment
- —
- Registry id
- NCT00003670
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.